News TaiMed Biologics Inc.

Equities

4147

TW0004147004

End-of-day quote Taipei Exchange Other stock markets 06:00:00 2024-04-25 pm EDT			5-day change	1st Jan Change
83 ^TWD	+0.61%		-0.12%	+1.22%

Mar. 20	TaiMed Biologics Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
Mar. 13	Taimed Biologics and AcedrA Biopharmaceticals Partner to Commercialize Trogarzo in the Middle East and North Africa Region	CI

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

TaiMed Biologics Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 20	CI
Taimed Biologics and AcedrA Biopharmaceticals Partner to Commercialize Trogarzo in the Middle East and North Africa Region	Mar. 13	CI
Taimed Announces Its Marketing Partner Received Refusal to File Letter for Trogarzo Intramuscular Method of Administration sBLA from the US FDA	Feb. 28	CI
TaiMed Biologics Inc. Receives Patent Approval from the Taiwan Intellectual Property Office for Improving the Pharmacokinetic Performance of TMB-365 Using Histidine Modification Technology	Feb. 21	CI
TaiMed Biologics Inc. Announces US FDA Grants Fast Track Designation to TMB-365/TMB-380 Long-Acting Combination Therapy for HIV Infection	Feb. 06	CI
TaiMed Biologics Inc. Revises the Phase 2 Clinical Study Design of Bi-Monthly Dosing of TMB-365/TMB-380 Combination for the Treatment of HIV Infection	Dec. 21	CI
Taimed Biologics Inc. Announces US FAD Approves the sBLA for the IV Push Administration of the Loading Dose of Trogarzo	Dec. 13	CI
TaiMed Biologics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 14	CI
Theratechnologies Reports Results from Trogarzo Intramuscular Administration Study; Tesamorelin Poster Presentation	23-10-13	MT
TaiMed Biologics Inc. Announces Results from Trogarzo Intramuscular (IM) Administration Study	23-10-13	CI
TaiMed Biologics Inc. Completes Data Analysis of the Clinical Trial Sentinel Group for the TMB-365 and TMB-380 Combination as Expected and Confirms the Dosing for Future Execution	23-09-06	CI
TaiMed Biologics Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-11	CI
TaiMed Biologics Inc. Completes the Last Patient Visit of the Sentinel Group in the Clinical Study Evaluating Long-Acting TMB-365/TMB-380 Combination Maintenance Therapy	23-06-28	CI
TaiMed Biologics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-12	CI
TaiMed Biologics Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-10	CI
TaiMed Biologics Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-10	CI
TaiMed Biologics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-10	CI
US FDA Approves the Supplemental Biologicslicense Application for Intravenous (IV) Pushadministration of Trogarzo	22-10-03	CI
TaiMed Biologics Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-14	CI
TaiMed Biologics : First Patient Enrolled in the Study Evaluating Bi-monthly and Quarterly Dosing of the Long-Acting TMB-365/TMB-380 mAb Combination Maintenance Therapy	22-07-28	PU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News TaiMed Biologics Inc.

Equities

4147

TW0004147004

Summary

Filters